This company has introduced a comprehensive Hepatitis C Virus (HCV) genotyping proficiency program available to laboratories to test their molecular diagnostics.
HCV genotype has been found to be an independent predictor of sustained virological response to therapy. Patients infected with HCV genotypes 2 or 3 are more likely to respond to interferon plus ribavirin therapy than those infected with other genotypes. Treatment times can be cut in half for these individuals, minimizing side effects. Consequently, HCV genotype testing provides the physician with an important tool for patient management.
The proficiency program utilizes LabQC.org, a secure, proprietary Internet reporting system for data entry and results verification.
AcroMetrix
www.acrometrix.com
Keywords: proficiency testing, molecular diagnostics, HIV, HCV, oncology
